Implementation and Outcome of Minimally Invasive Pancreatoduodenectomy in Europe:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1,336 enrolled

Overview

A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

The European registry for Minimally Invasive Pancreatic Surgery (E-MIPS) is an E-AHPBA endorsed registry with the aim to monitor and safeguard the introduction of MIPD in Europe. International multicenter audit-based studies focusing on outcomes of minimally invasive pancreatoduodenectomy (MIPD) are lacking. A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Study Type

OBSERVATIONAL

Enrollment

1,336

Conditions

Pancreas Disease

Interventions

No interventionOTHER

all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Data from all patients who underwent R-MIPD and L-MIPD between January 1st 2019 and December 31st 2021 were included Exclusion Criteria: * Other pancreatic procedures * Hybrid approaches (reconstruction phase open) * Procedures with insufficient baseline data / missing primary outcome data.

Locations (1)

Amsterdam UMC, locatie AMC

Amsterdam, North Holland, Netherlands

Outcomes

Primary Outcomes

Major morbidity

Time frame: 30 days

30-day/in-hospital mortality.

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.